worldpharmaceuticals.net
Lilly secures FDA approval for Omvoh to treat Crohn's disease
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.
The approval is based on Phase 3 results showing clinical remission and endoscopic healing at one year, outcomes that matter to people living with IBD.
Adults with moderately to severely active Crohn’s disease, patients with ulcerative colitis interested in IL-23 therapies, clinicians who treat IBD, and researchers following biologic drug development.
What To Know
FDA approval: The article reports that Eli Lilly’s Omvoh (mirikizumab-mrkz), an IL-23 p19 antagonist, received FDA approval to treat adults with moderately to severely active Crohn’s disease.
It notes Omvoh was already approved for ulcerative colitis and summarizes key Phase 3 VIVID-1 results cited by the company, including clinical remission and endoscopic response at one year, as well as common adverse reactions and ongoing studies (VIVID-2 OLE) and regulatory submissions in other regions.
Omvoh is a biologic that targets the IL-23 pathway and is now approved in the US for two IBD indications (Crohn’s disease and ulcerative colitis). The company-reported Phase 3 data highlighted rates of clinical remission and endoscopic healing at one year and earlier endoscopic improvements at three months versus placebo.
The article lists labeled warnings and common side effects consistent with the drug’s safety profile. Practical points: This is a regulatory approval announcement summarizing sponsor-reported trial outcomes and safety remarks. It does not provide full study datasets, prescribing details, or comparative effectiveness versus other IBD treatments.
Patients should discuss with their clinicians whether Omvoh is an appropriate option and review official prescribing information for warnings and monitoring requirements.
This article is an industry news report summarizing Lilly’s announcement and sponsor-reported Phase 3 results. It does not replace full peer-reviewed study publications, regulatory labeling, or clinical guidance. Safety notes and real-world access (insurance, guidelines) will affect how quickly patients may be prescribed this medicine.
